- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02742727
CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma
December 4, 2016 updated by: PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.
Study Overview
Status
Unknown
Conditions
- Acute Myeloid Leukemia
- Angioimmunoblastic T-cell Lymphoma
- Hepatosplenic T-cell Lymphoma
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Extranodal NK/T-cell Lymphoma, Nasal Type
- T-cell Prolymphocytic Leukemia
- T-cell Large Granular Lymphocytic Leukemia
- Peripheral T-cell Lymphoma, NOS
- Enteropathy-type Intestinal T-cell Lymphoma
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
10
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215123
- Recruiting
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
-
Principal Investigator:
- Xiang Sun, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Male and female subjects with CD7+ malignancies in patients with no available curative treatment options who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled:
- Eligible diseases: CD7 positive relapsed or refractory Leukemia and Lymphoma. ᅳ Acute myeloid leukemia, previously identified as CD7+ ᅳ Precursor T lymphoblast leukemia/lymphoma ᅳ T-cell prolymphocytic leukemia ᅳ T-cell large granular lymphocytic leukemia ᅳ Peripheral T-cell lymphoma, NOS ᅳ Angioimmunoblastic T-cell lymphoma ᅳ Extranodal NK/T-cell lymphoma, nasal type ᅳ Enteropathy-type intestinal T-cell lymphoma ᅳ Hepatosplenic T-cell lymphoma
- Patients 18 years of age or older, and must have a life expectancy > 12 weeks.
- CD7 is expressed in malignancy tissues by immuno-histochemical (IHC) or Flow cytometry.
- Assessable disease as measured by laboratory and bone marrow examinations.
- Eastern cooperative oncology group (ECOG) performance status of 0-2 or karnofsky performance status (KPS) score is higher than 60.
- Females of child-bearing potential must have a negative pregnancy test and all subjects must agree to use an effective method of contraception for up to two weeks after the last infusion of CAR-pNK cells.
- Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: serum creatinine ≤ 2.5mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg/dL. These tests must be conducted within 7 days prior to registration.
- Ability to give informed consent.
Exclusion Criteria:
- Patients with symptomatic central nervous system (CNS) involvement.
- Pregnant or nursing women may not participate.
- Known HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- Serious illness or medical condition which would not permit the patient to be managed according to the protocol, including active uncontrolled infection, major cardiovascular, coagulation disorders, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or psychiatric or emotional disorders.
- Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- Previously treatment with any gene therapy products.
- The existence of unstable or active ulcers or gastrointestinal bleeding.
- Patients with a history of organ transplantation or are waiting for organ transplantation.
- Patients need anticoagulant therapy (such as warfarin or heparin).
- Patients need long-term antiplatelet therapy (aspirin at a dose > 300mg/d; clopidogrel at a dose > 75mg/d).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CAR-pNK Cell immunotherapy
Enrolled patients will receive CAR-pNK cell immunotherapy with a novel specific chimeric antigen receptor targeting CD7 antigen by infusion.
|
The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains.
These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events attributed to the administration of the anti-CD7 CAR-pNK cells
Time Frame: 2 years
|
Determine the toxicity profile of the CD7 targeted CAR-pNK cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical response to CD7 CAR-pNK cell infusions
Time Frame: Safety follow-up is 100 days from last CAR-pNK infusion
|
Patients with measurable disease will be assessed for the response of their disease to CD7 CAR-pNK cell treatment.
|
Safety follow-up is 100 days from last CAR-pNK infusion
|
Determine the existence of CD7-CAR-pNK in vivo
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Lin Yang, Ph.D., PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (Anticipated)
March 1, 2017
Study Completion (Anticipated)
March 1, 2018
Study Registration Dates
First Submitted
March 31, 2016
First Submitted That Met QC Criteria
April 13, 2016
First Posted (Estimate)
April 19, 2016
Study Record Updates
Last Update Posted (Estimate)
December 6, 2016
Last Update Submitted That Met QC Criteria
December 4, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Leukemia, Lymphoid
- Lymphadenopathy
- Leukemia, T-Cell
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma
- Leukemia
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Lymphoma, Extranodal NK-T-Cell
- Immunoblastic Lymphadenopathy
- Leukemia, Prolymphocytic
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Large Granular Lymphocytic
- Enteropathy-Associated T-Cell Lymphoma
- Leukemia, Prolymphocytic, T-Cell
Other Study ID Numbers
- PG-107-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myeloid Leukemia
-
University of PennsylvaniaActive, not recruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia, Refractory | Acute Myeloid Leukemia, PediatricUnited States
-
Terrence J Bradley, MDImago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...RecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in RelapseUnited States
-
Bhavana BhatnagarCTI BioPharmaCompletedRecurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
-
National Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Washington University School of MedicineWithdrawnRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
C. Babis AndreadisGateway for Cancer Research; AVEO Pharmaceuticals, Inc.TerminatedAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
Kronos BioActive, not recruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States, Spain
-
Massachusetts General HospitalExelixisCompletedRefractory Acute Myeloid Leukemia | Relapsed Acute Myeloid LeukemiaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingAcute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Therapy-Related Acute Myeloid LeukemiaUnited States
Clinical Trials on anti-CD7 CAR-pNK cells
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingAutoimmune Diseases | Crohn Disease | Ulcerative Colitis | Dermatomyositis | Still DiseaseChina
-
Shanghai General Hospital, Shanghai Jiao Tong University...RecruitingAnaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Peripheral T Cell Lymphoma | T-cell Acute Lymphoblastic Leukemia | T Lymphoblastic Leukemia/LymphomaChina
-
Shenzhen University General HospitalRecruiting
-
iCell Gene TherapeuticsPeking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.RecruitingT-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic LymphomaChina
-
Bioceltech Therapeutics, Ltd.RecruitingT Cell Lymphoblastic LymphomaChina
-
The First Affiliated Hospital of Soochow UniversityAffiliated Hospital of Jiangnan University; The Affiliated Nanjing Drum Tower... and other collaboratorsRecruiting
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.The First People's Hospital of Hefei; Hefei Binhu HospitalUnknownHepatocellular Carcinoma | Malignant Glioma of Brain | Non-small Cell Lung Cancer | Gastric Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma | Triple-Negative Invasive Breast CarcinomaChina
-
Shenzhen Geno-Immune Medical InstituteThe Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...RecruitingAcute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell LymphomaChina
-
Shenzhen Geno-Immune Medical InstituteRecruitingAcute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell LymphomaChina
-
Zhejiang UniversityYake Biotechnology Ltd.RecruitingNeoplasms | Hematologic DiseasesChina